Comparison of Retuximab and Ochrelysimab in Relapsing-Remitting Multiple Sclerosis

This chapter discusses a study comparing the effectiveness of retuximab and ochrelysimab, two monoclonal antibodies used as disease-modifying therapies for relapsing-remitting multiple sclerosis. The results showed differences in relapse rates but no difference in disability accumulation, highlighting the need for further research.